• Home
• About Us
  • Company
  • History
  • Management
  • Brochure (pdf)
• Pipeline
  • Cancer Drug Programmes
  • Chk1
  • FLT4
  • Aurora
  • FLT3
  • PLK
  • B-raf
  • FASN
• Partnering
  • Research Services
  • Out-licensing
• Investors
  • Board of Directors
  • Information Disclosure
  • Investor News
  • Company Advisors
  • Research
• News & Events
  • Press Release
  • Publications
  • Events
• Contact Us
  • Careers
  • Contact Us
  • Map & Directions

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, JAPAN OR THE REPUBLIC OF SOUTH AFRICA OR ANY JURISDICTION IN WHICH SUCH PUBLICATION IS UNLAWFUL.

 Sareum Holdings PLC

(“Sareum” or “the Company”)

Additional Placing 

Sareum (AIM: SAR), the specialist cancer drug discovery business, is pleased to announce it has conditionally raised a further £50,000, before expenses, by way of a placing by Hybridan LLP of 20,000,000 new ordinary shares of 0.025p each in the capital of the Company (the “Placing Shares”) at 0.25p per share. This placing of £50,000 is in addition to the £765,000 raised by Hybridan in the placings which were announced on 8 September 2009 and 12 October 2009.

Sareum intends to use the proceeds of the placing primarily to progress its cancer research programmes.

Application has been made to the London Stock Exchange for the Placing Shares to be admitted to trading on AIM and it is expected that admission will become effective and trading will commence on 19 October 2009. The Placing Shares will rank pari passu with the existing ordinary shares of the Company.

Following the admission of the Placing Shares to trading on AIM, the Company will have a total of 1,175,597,713 shares in issue.

Tim Mitchell, Founder and CEO commented:

“Sareum has raised a total of £815,000 over the last two months which will enable us progress our cancer research programmes for the foreseeable future. We are delighted with this support from investing institutions.” 

Enquiries:  

This announcement is for information purposes only and does not constitute an offer or invitation to acquire or dispose of any securities or investment advice in any jurisdiction.

Hybridan LLP, which is authorised and regulated in the United Kingdom by the Financial Services Authority, is acting exclusively for the Company and no-one else in connection with the Placing and will not be responsible to anyone other than the Company for providing the protections afforded to clients of Hybridan LLP or for providing advice in relation to the Placing or any transaction or any other matters referred to herein.

Past performance is no guide to future performance and persons needing advice should consult an independent financial adviser.

The information contained in this announcement is not for release, publication or distribution, directly or indirectly, to persons in the United States, Australia, Canada, Japan or the Republic of South Africa or in any jurisdiction in which such publication or distribution is unlawful. The Placing Shares have not been and will not be registered under the United States Securities Act of 1933, as amended, or under the laws of any state of the United States. This announcement does not constitute an offer to sell or issue, or the solicitation of an offer to buy or subscribe for, securities in the United States, Australia, Canada, Japan or the Republic of South Africa or in any jurisdiction in which such offer or solicitation is unlawful and should not be relied upon in connection with any decision to acquire Placing Shares or other securities in the capital of the Company. There will be no public offer of Placing Shares in the United Kingdom or elsewhere.

Notes for editors:

About Sareum Holdings plc

Sareum is a drug discovery company, headquartered in Cambridge UK, that is focused on producing targeted small molecule therapeutics to address unmet medical needs, primarily in cancer.

Requires RSS news reader

Requires MS Word

Requires Adobe Acrobat Reader